8/3/2020 10:06:57 PM
Alterity : New Data Independently Confirms And Extends Laboratory Findings And Expands Safety Profile Of ATH434
6/29/2020 11:32:40 PM
Alterity Therapeutics Says Meeting With US FDA Provides Development Pathway For ATH434
5/20/2020 9:01:13 PM
Alterity Therapeutics Presents Data On ATH434 To American Academy Of Neurology
2/7/2020 8:01:56 AM
Alterity Therapeutics Gets Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement
1/31/2019 9:04:25 AM
Prana Gets First Orphan Drug Designation From FDA For Treatment Of Multiple System Atrophy
6/13/2018 9:10:01 PM
Prana To Commence Phase 1 Trial Of PBT434 For Treatment Of Parkinsonian Diseases
1/5/2018 1:20:37 PM
B. Riley FBR Starts Prana Biotechnology Ltd (PRAN) At Buy With $4.00 Price Target